StartUPDATES: New developments for healthcare startups
Read about news from Seven Bridges, Outcomes4Me, Carrum Health and more.
foresite capital
VelosBio raises $137M Series B round to support suite of ROR1-targeting cancer drugs
The company is currently running a Phase I study of its lead candidate, the antibody-drug conjugate VLS-101, in patients with lymphomas and leukemias. It has two additional antibody-drug conjugates and a bispecific antibody in preclinical development.